

Walter J Storkus

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1898024/walter-j-storkus-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151
papers

7,184
citations

48
h-index

80
g-index

162
ext. papers

7,934
ext. citations

7.4
avg, IF

5.38
L-index

#	Paper	IF	Citations
151	alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. <i>Cancer Research</i> , 2004 , 64, 5934-7	10.1	413
150	Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. <i>Journal of Immunology</i> , 2009 , 183, 3720-30	5.3	381
149	Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. <i>Journal of Immunology</i> , 2003 , 171, 2366-73	5.3	300
148	Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. <i>Journal of Experimental Medicine</i> , 2002 , 196, 619-28	16.6	263
147	Identification of T-Cell Epitopes. <i>Journal of Immunotherapy</i> , 1993 , 14, 94-103	5	188
146	Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. <i>Laboratory Investigation</i> , 2003 , 83, 683-95	5.9	181
145	FLT3 ligand induces the generation of functionally active dendritic cells in mice. <i>Cellular Immunology</i> , 1997 , 179, 174-84	4.4	174
144	Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. <i>Journal of Translational Medicine</i> , 2007 , 5, 10	8.5	139
143	Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. <i>Journal of Experimental Medicine</i> , 2002 , 195, 473-83	16.6	129
142	Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. <i>European Journal of Immunology</i> , 1996 , 26, 1335-41	6.1	122
141	Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. <i>Journal of Immunology</i> , 2002 , 168, 1831-9	5.3	119
140	Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. <i>Human Gene Therapy</i> , 1994 , 5, 1493-506	4.8	117
139	Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses. <i>Blood</i> , 2000 , 96, 1857-1864	2.2	115
138	Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. <i>International Journal of Cancer</i> , 2011 , 129, 2158-70	7.5	112
137	EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. <i>Neoplasia</i> , 2005 , 7, 717-22	6.4	112
136	Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. <i>European Journal of Immunology</i> , 1997 , 27, 2702-7	6.1	109
135	Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. <i>Cancer Research</i> , 2003 , 63, 4481-9	10.1	97

134	Helper role of NK cells during the induction of anticancer responses by dendritic cells. <i>Molecular Immunology</i> , 2005 , 42, 535-9	4.3	96
133	Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. <i>Clinical Cancer Research</i> , 2002 , 8, 1787-93	12.9	96
132	Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. <i>Cancer Research</i> , 2003 , 63, 6378-86	10.1	88
131	Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. <i>Clinical Cancer Research</i> , 2002 , 8, 2851-5	12.9	87
130	DNA immunization targeting the skin: molecular control of adaptive immunity. <i>Journal of Investigative Dermatology</i> , 1998 , 111, 183-8	4.3	79
129	Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. <i>Vaccine Journal</i> , 2000 , 7, 145-54		79
128	IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 284-93	6.5	79
127	Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer 2015 , 3,		78
126	Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. <i>Journal of Immunology</i> , 2002 , 168, 1823-30	5.3	76
125	Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. <i>Journal of Immunotherapy</i> , 2007 , 30, 75-82	5	73
124	Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. <i>Cancer Research</i> , 2006 , 66, 4478-87	10.1	70
123	Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 1995 , 41, 111-21	7.4	66
122	Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. <i>Cancer Gene Therapy</i> , 1999 , 6, 73-80	5.4	65
121	Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. <i>Clinical Cancer Research</i> , 2005 , 11, 226-31	12.9	63
120	IL-36 β Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. <i>Cancer Cell</i> , 2015 , 28, 296-306	24.3	62
119	Effect of renal cell carcinomas on the development of type 1 T-cell responses. <i>Clinical Cancer Research</i> , 2004 , 10, 6360S-6S	12.9	62
118	Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 440-54	6.5	62
117	Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. <i>European Journal of Immunology</i> , 1994 , 24, 765-8	6.1	61

116	Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. <i>Human Immunology</i> , 1994 , 39, 79-86	2.3	61
115	IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. <i>Human Gene Therapy</i> , 1995 , 6, 1607-24	4.8	60
114	Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. <i>Immunological Investigations</i> , 2000 , 29, 121-5	2.9	56
113	Gene-based strategies for the immunotherapy of cancer. <i>Journal of Molecular Medicine</i> , 1997 , 75, 478-91	5.5	55
112	Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. <i>Cancer Research</i> , 2004 , 64, 8381-8	10.1	54
111	Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. <i>Cancer Research</i> , 2006 , 66, 5883-91	10.1	53
110	Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. <i>Cancer Research</i> , 2007 , 67, 6451-8	10.1	53
109	Tumor-derived vascular pericytes anergize Th cells. <i>Journal of Immunology</i> , 2013 , 191, 971-81	5.3	52
108	Proinflammatory Cytokines and CD40 Ligand Enhance Cross-Presentation and Cross-Priming Capability of Human Dendritic Cells Internalizing Apoptotic Cancer Cells. <i>Journal of Immunotherapy</i> , 2001 , 24, 162-171	5	52
107	Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. <i>Melanoma Research</i> , 2012 , 22, 236-43	3.3	51
106	Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. <i>Cancer Research</i> , 2005 , 65, 8461-70	10.1	50
105	Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. <i>Journal of Immunology</i> , 2005 , 175, 2730-40	5.3	48
104	Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. <i>Journal of Translational Medicine</i> , 2004 , 2, 40	8.5	46
103	Chronic inflammation and immunologic-based constraints in malignant disease. <i>Immunotherapy</i> , 2011 , 3, 1265-74	3.8	44
102	Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. <i>Cancer Research</i> , 2012 , 72, 3196-206	10.1	43
101	Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. <i>Cancer</i> , 2007 , 110, 1469-77	6.4	42
100	Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. <i>Journal of Immunotherapy</i> , 2008 , 31, 254-62	5	41
99	Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin?. <i>Pigment Cell & Melanoma Research</i> , 2003 , 16, 254-60		40

98	Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. <i>Journal of Immunotherapy</i> , 1998 , 21, 149-57	5	40
97	Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. <i>Cancer Research</i> , 2004 , 64, 5830-8	10.1	38
96	Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. <i>Cancer Research</i> , 2002 , 62, 5853-8	10.1	38
95	Tbet and IL-36 cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. <i>Onc Immunology</i> , 2017 , 6, e1322238	7.2	37
94	Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. <i>Blood</i> , 2013 , 121, 2923-33	2.2	37
93	Association of IL-36 with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 109-120	7.4	37
92	A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. <i>Cancer Research</i> , 2010 , 70, 9041-52	10.1	36
91	Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. <i>Journal of Immunology</i> , 2012 , 188, 1782-8	5.3	36
90	Dendritic cell based therapy of cancer. <i>Advances in Experimental Medicine and Biology</i> , 1997 , 417, 551-69	3.6	35
89	Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment. <i>Advances in Cancer Research</i> , 2015 , 128, 197-233	5.9	33
88	Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. <i>Immunological Investigations</i> , 2012 , 41, 680-710	2.9	33
87	Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1843-1849	8.9	32
86	Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. <i>Molecular Therapy</i> , 2011 , 19, 805-14	11.7	32
85	Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. <i>Journal of Immunological Methods</i> , 2002 , 261, 145-56	2.5	32
84	Murine models of cancer cytokine gene therapy using interleukin-12. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 275-83	6.5	32
83	Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. <i>Cancer Research</i> , 2009 , 69, 6995-7003	10.1	31
82	Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. <i>Carcinogenesis</i> , 2020 , 41, 625-633	4.6	31
81	IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. <i>Journal of Immunology</i> , 2005 , 174, 7194-201	5.3	30

80	Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. <i>OncolImmunology</i> , 2014 , 3, e27589	7.2	29
79	Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. <i>Journal of Immunology</i> , 2009 , 183, 7250-8	5.3	28
78	Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. <i>Laryngoscope</i> , 1998 , 108, 261-8	3.6	28
77	Combinational FLT3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. <i>Cancer Research</i> , 2006 , 66, 4895-903	10.1	26
76	Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. <i>Cancer Research</i> , 2007 , 67, 10012-8	10.1	26
75	EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. <i>Transplant Immunology</i> , 2005 , 14, 109-16	1.7	26
74	Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. <i>Clinical Cancer Research</i> , 2004 , 10, 3301-8	12.9	26
73	Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. <i>Cancer Gene Therapy</i> , 2003 , 10, 549-58	5.4	26
72	Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. <i>Journal of Immunology</i> , 2008 , 181, 104-8	5.3	25
71	Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals. <i>Transplantation</i> , 2000 , 70, 1507-15	1.8	25
70	STING Agonists as Cancer Therapeutics. <i>Cancers</i> , 2021 , 13,	6.6	25
69	Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity. <i>Journal of Immunology</i> , 2015 , 194, 5937-47	5.3	24
68	miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. <i>Journal of Translational Medicine</i> , 2016 , 14, 84	8.5	24
67	Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. <i>Journal of Immunology</i> , 2008 , 181, 7721-7	5.3	24
66	DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature. <i>Molecular Therapy</i> , 2013 , 21, 1958-68	11.7	23
65	CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. <i>Cancer Research</i> , 2008 , 68, 8076-84	10.1	23
64	A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6. <i>Clinical Cancer Research</i> , 2007 , 13, 6796-806	12.9	23
63	IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. <i>Journal of Immunotherapy</i> , 2009 , 32, 793-802	5	22

62	Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity. <i>Frontiers in Immunology</i> , 2013 , 4, 388	8.4	21
61	DC expressing transgene Foxp3 are regulatory APC. <i>European Journal of Immunology</i> , 2010 , 40, 480-93	6.1	21
60	JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients. <i>Journal of Biomedicine and Biotechnology</i> , 2010 , 2010, 935764		20
59	Tumor-associated mesenchymal stem cells inhibit naïve T cell expansion by blocking cysteine export from dendritic cells. <i>International Journal of Cancer</i> , 2016 , 139, 2068-81	7.5	19
58	Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. <i>OncolImmunology</i> , 2016 , 5, e1146841	7.2	19
57	Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. <i>American Journal of Transplantation</i> , 2003 , 3, 1369-77	8.7	18
56	IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. <i>European Journal of Immunology</i> , 2008 , 38, 2865-73	6.1	17
55	Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients. <i>Frontiers in Oncology</i> , 2014 , 4, 266	5.3	15
54	Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. <i>OncolImmunology</i> , 2014 , 3, e959321	7.2	14
53	Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. <i>Journal of Immunology</i> , 2010 , 185, 2895-902	5.3	14
52	Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. <i>Human Immunology</i> , 2005 , 66, 762-72	2.3	14
51	Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice. <i>Journal of Controlled Release</i> , 2020 , 318, 270-278	11.7	14
50	Molecular mimicry of MAGE-A6 and HF-2 epitopes in the induction of antitumor CD8 T-cell responses. <i>OncolImmunology</i> , 2014 , 3, e954501	7.2	13
49	Focus on FOCIS: interleukin 2 treatment associated autoimmunity. <i>Clinical Immunology</i> , 2008 , 127, 123-99		13
48	IL-12 production by human monocyte-derived dendritic cells: looking at the single cell. <i>Journal of Immunotherapy</i> , 2005 , 28, 306-13	5	13
47	Dendritic cell-based vaccines and therapies for cancer. <i>Expert Opinion on Biological Therapy</i> , 2002 , 2, 919-28	5.28	13
46	STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment 2021 , 9,		13
45	Tumor-Derived Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death. <i>Cancer Immunology Research</i> , 2017 , 5, 493-502	12.5	12

44	Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. <i>European Journal of Immunology</i> , 2010 , 40, 1950-62	6.1	12
43	Augmentation of type-1 polarizing ability of monocyte-derived dendritic cells from chronically immunosuppressed organ-transplant recipients. <i>Transplantation</i> , 2005 , 79, 451-9	1.8	12
42	Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4 T cells combined with agonist α GITR mAb promotes durable CD8 T-cell-dependent antitumor immunity. <i>OncolImmunology</i> , 2017 , 6, e1315487	7.2	11
41	Immunotherapeutic Targeting of Tumor-Associated Blood Vessels. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 1036, 191-211	3.6	11
40	Integrating costimulatory agonists to optimize immune-based cancer therapies. <i>Immunotherapy</i> , 2009 , 1, 249-64	3.8	11
39	Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice. <i>OncolImmunology</i> , 2017 , 6, e1290035	7.2	10
38	Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. <i>Immunotherapy</i> , 2016 , 8, 1205-18	3.8	10
37	Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. <i>Critical Reviews in Immunology</i> , 2007 , 27, 485-93	1.8	10
36	Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO. <i>Frontiers in Immunology</i> , 2016 , 7, 301	8.4	10
35	Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. <i>Molecular Therapy</i> , 2012 , 20, 644-51	11.7	7
34	Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. <i>Journal of Immunology</i> , 2007 , 178, 3400-8	5.3	7
33	Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. <i>Melanoma Research</i> , 2006 , 16, 165-74	3.3	7
32	Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells. <i>Journal of Biological Chemistry</i> , 2020 , 295, 15636-15649	5.4	7
31	Class I-like CD1A-C do not protect target cells from NK-mediated cytotoxicity. <i>Cellular Immunology</i> , 1996 , 167, 154-6	4.4	6
30	Dysregulated NF- κ B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. <i>Cancer Immunology Research</i> , 2020 , 8, 1554-1567	12.5	6
29	STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development. <i>Frontiers in Immunology</i> , 2021 , 12, 690105	8.4	6
28	Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.. <i>Molecular Cancer</i> , 2021 , 20, 171	42.1	6
27	Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1133-1141	7.4	5

26	Shock block for improved immunotherapy. <i>OncImmunology</i> , 2012 , 1, 1427-1429	7.2	5
25	Progenipoiectin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model. <i>International Journal of Cancer</i> , 2002 , 100, 586-91	7.5	5
24	Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. <i>European Journal of Immunology</i> , 1996 , 26, 2613-23	6.1	5
23	Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 165-177	2.2	5
22	Tumor Arrests DN2 to DN3 Pro T Cell Transition and Promotes Its Conversion to Thymic Dendritic Cells by Reciprocally Regulating Notch1 and Ikaros Signaling. <i>Frontiers in Immunology</i> , 2020 , 11, 898	8.4	4
21	Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation. <i>Frontiers in Immunology</i> , 2021 , 12, 629519	8.4	4
20	Update on vaccine development for renal cell cancer. <i>Research and Reports in Urology</i> , 2010 , 2, 125-41	1.3	3
19	Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines	23-43	3
18	IL-36 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1240, 95-110	3.6	3
17	Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. <i>Journal of Immunotherapy</i> , 2007 , 30, 577-90	5	2
16	The immunology of DNA vaccines. <i>Methods in Molecular Medicine</i> , 2000 , 29, 37-64		2
15	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma	2021 , 9,	2
14	PET Imaging of VLA-4 in a New BRAF Mouse Model of Melanoma. <i>Molecular Imaging and Biology</i> , 2021 , 1	3.8	2
13	RGS5-TGFβSmad2/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth. <i>Cell Death and Differentiation</i> , 2021 , 28, 3052-3076	12.7	2
12	Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors	2021 , 9,	2
11	CD4+ T-Cell-Mediated Immunity to Cancer	2004 , 67-86	1
10	Monitoring antigen-specific T cell responses using real-time PCR. <i>Methods in Molecular Biology</i> , 2014 , 1186, 65-74	1.4	1
9	Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes	1995 , 41, 111	1

- 8 Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines. *SLAS Discovery*, **2021**, 26, 712-729 3.4 1
- 7 EphA2: A Novel Target in Renal Cell Carcinoma **2009**, 347-366 0
- 6 Neopeptides as Difference Makers for General Cancer Vaccines?. *Clinical Cancer Research*, **2020**, 26, 4429-4431 1.4
- 5 Inhibition of HSPs for Enhanced Immunity **2018**, 157-180
- 4 Vaccines in RCC: Clinical and Biological Relevance **2015**, 483-525
- 3 Vascular Normalization, T Cell Trafficking and Anti-tumor Immunity. *Resistance To Targeted Anti-cancer Therapeutics*, **2016**, 51-76 0.3
- 2 Dendritic Cell Maturation Versus Polarization in Tumor Escape **2009**, 257-268
- 1 Molecular Immunotherapeutics and Vaccines for Renal Cell Carcinoma and Its Vasculature **2013**, 371-383